PHI bolsters Nordic sales presence with new distribution agreement between Altium and Kem-En-Tec Nordic
Phase Holographic Imaging (PHI) is pleased to announce a new distribution agreement between its global distribution partner, Altium, and Kem-En-Tec Nordic (“Kem-En-Tec”), a lab supplier dedicated to supporting BioScience labs. With Kem-En-Tec’s extensive experience in delivering products to universities and the health sector across the Nordic countries, PHI aims to enhance its market presence in Denmark, Sweden, Norway, Finland and Iceland.
PHI’s global distribution partner Altium entered a subcontract with Kem-En-Tec Nordic, a lab supplier with a significant presence in Denmark, Sweden, Norway, Finland and Iceland. This agreement is designed to expand the reach and sales performance of PHI's HoloMonitor technology in the Nordics.
PHI CEO, Patrik Eschricht, comments:
“We are thrilled to work with Kem-En-Tec Nordic, a company with a solid reputation and deep connections within the Nordic bioscience community. The Nordic market is particularly attractive due to its strong focus on innovation and research. This agreement will help us expand our market reach, ensuring that more researchers and life sciences professionals can benefit from our HoloMonitor technology."
Kem-En-Tec Nordic has established itself as a recognized supplier through numerous framework agreements and close collaborations with universities and the health sector in the Nordic countries. This distribution agreement is expected to bolster PHI’s sales efforts for the HoloMonitor technology and PHI’s overall product portfolio, leveraging Kem-En-Tec’s established reputation and market reach.
For additional information, please contact:
Lisa Bodily
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis
About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI’s current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.